Skip to main content

Site notifications

Notice for sapropterin Dihydrochloride (BioMarin Pharmaceuticals Australia Pty Ltd)

Active ingredients
sapropterin Dihydrochloride
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet
Indication
For the treatment of hyperphenylalaninemia (HPA) in patients with phenylketonuria (PKU) or tetrahydrobiopterin- (BH4-) deficiency.

Help us improve the Therapeutic Goods Administration site